Occasional review

Functional antagonism: tolerance produced by inhaled β_2 agonists

D W Cockcroft, V A Swystun

The development of tolerance to the beneficial effects of inhaled β_2 agonists has been suggested as one possible explanation for the deleterious effects of frequent use of these agents in asthma.¹ The two main beneficial pharmacological effects of inhaled β_2 agonists in asthma are bronchodilation and functional antagonism.² Although it has been difficult to show appreciable tolerance to the bronchodilator efficacy of these agents,³ regular use of inhaled β_2 agonists predictably causes tolerance to the functional antagonist (bronchoprotective effect) of these drugs.¹ In this review we will discuss the topic of tolerance to the bronchoprotective effect of inhaled β_2 agonist and its potential clinical relevance.

Functional antagonism

Functional antagonism is a term used to describe the ability of a pharmacological agent to prevent bronchoconstriction non-selectively. The term "non-selective" is used to contrast this with "selective" inhibition of bronchoconstriction – for example, inhibition of cholinergic bronchoconstriction by anticholinergic drugs or inhibition of histamine bronchoconstriction by H_1 blockers. Functional antagonism is a property shared by the bronchodilator classes of medications. β_2 agonists, particularly those administered via the inhaled route, are the most potent functional antagonists in asthma.² It has been suggested that tests of functional antagonism might be an alternative means of assessing the clinical effect and clinical duration of effect of inhaled β_2 agonists.²

β_2 agonists prevent induced bronchoconstriction predominantly by an effect on airway smooth muscle β_2 receptors.⁴ These are the same receptors that are responsible for bronchodilation. It has been suggested that the mechanism of bronchodilation and functional antagonism are different, based on a poor correlation between magnitude of bronchodilation and magnitude of functional antagonism. Alternatively, the difference might be due to the difference in the way in which these are measured. Bronchodilation is essentially a "closed end" scale where improvement in flow rates is limited by return to "normal" and may be near maximal at relatively low doses of β_2 agonist. By contrast, functional antagonism, as meas-

ured by dose response curves (see below), is a more "open ended" scale. Failure of correlation between these two may be merely a result of measurement differences rather than a difference in mechanisms. Inhaled β_2 agonists may have additional effects in protecting against bronchoconstriction due to stimuli which involve mast cell mediator release. β_2 agonists suppress the release of mast cell mediators and provide greater protection against mast cell stimuli such as AMP and allergen than they do against methacholine; this is probably due to an additive protective effect on mast cell and smooth muscle β receptors in the former compared with smooth muscle only for the latter.⁴

The functional antagonism effect of an inhaled β_2 agonist is assessed in the laboratory using bronchoprovocation tests performed before and after administration of the inhaled β_2 agonist.^{2,4} The difference between the two tests represents the magnitude of the functional antagonism. Stimuli for bronchoprovocation can be categorised as non-sensitising (histamine, methacholine, other chemical mediators, exercise, cold air, non-isotonic aerosols, etc) or sensitising (allergens, occupational chemicals).⁵ Perhaps a more useful categorisation of bronchoprovocative stimuli is that of direct and indirect.⁶ Direct stimuli provoke bronchoconstriction by a direct effect on airway smooth muscle receptors. Histamine, methacholine, and, probably, arachidonic acid metabolites are examples of direct stimuli. Indirect stimuli provoke bronchoconstriction by one or more intermediate pathways such as mast cell mediator release, neurological reflexes, etc. The sensitising stimuli, the physical stimuli (exercise, cold air, non-isotonic aerosols), and a number of the chemical stimuli (AMP, β adrenergic blockers) are felt to be indirect. Since naturally occurring bronchoconstriction in asthmatic subjects is indirect (exercise, cold air, irritants, allergens, etc), the results of challenges with indirect stimuli has been hypothesised to have more clinical relevance for asthma.⁶

There are two major different methodologies for bronchoprovocation tests that lead to two different ways to measure functional antagonism. Most commonly, bronchoprovocation tests are done by administering doubling doses of the bronchoconstrictor stimulus at appropriate time intervals to establish

Division of
Respiratory Medicine,
Department of
Medicine, Royal
University Hospital,
University of
Saskatchewan,
Saskatoon,
Saskatchewan
S7N 0W8, Canada
D W Cockcroft
V A Swystun

Correspondence to:
Dr D W Cockcroft.

Received 13 May 1996
Accepted for publication
20 May 1996

either a provocation dose (PD) or a provocation concentration (PC) producing a given fall (usually 15% or 20%) in forced expiratory volume in one second (FEV₁). The terms PD₁₅, PC₂₀ are used to describe these end points. The doubling "dose" can be achieved by doubling the concentrations of the stimulus (as is often done with histamine,⁷ methacholine,^{4,7} and other chemical mediators⁴), or by doubling the duration of exposure as is frequently done with non-isotonic aerosols.^{8,9} The early asthmatic response (EAR) to allergen can also be assessed as an allergen PC₂₀.¹⁰ When using a bronchoconstrictor stimulus for which the results are expressed as a PC₁₅ or PC₂₀, functional antagonism produced by inhaled β₂ agonists is assessed by repeating the bronchoprovocation test at an appropriate time after the administration of the β₂ agonist. The PC₁₅/PC₂₀ is measured again. The degree of bronchoprotection can be assessed logarithmically by calculating the change in log PC₂₀. The Δlog₁₀ PC₂₀ is divided by the log of 2 (that is, Δlog₁₀ PC₂₀/0.3) to express the magnitude of the functional antagonism in "doubling doses" of protection.⁴ An alternative means of expressing the shift in PC₂₀ is non-logarithmically as, for example, fivefold, tenfold, etc.¹¹ Repeating an allergen challenge to measure PC₂₀ after an inhaled β₂ agonist can lead to a severe late asthmatic response (LAR).¹² When examining the allergen-induced EAR in this way, we routinely administer a single large dose of inhaled corticosteroid (beclomethasone dipropionate 500–1000 μg or equivalent) after completion of the EAR; this is known to inhibit the LAR.¹³

The second major bronchoprovocation method involves administration of a single maximal or near maximal stimulus. This is the traditional way in which exercise challenges have been done.¹⁴ Functional antagonism is assessed by repeating the "same dose" challenge after inhaled β₂ agonist and is expressed as the percentage reduction in the response – for example, exercise induced bronchoconstriction (EIB) is usually measured as a fall in FEV₁ – compared with the response to exercise following placebo.^{14,15} Functional antagonism is expressed as "percentage inhibition" by the following formula:

$$\% \text{ inhibition} = \frac{(\text{EIB after placebo} - \text{EIB after drug})}{\text{EIB after placebo}} \times 100$$

The effect of pharmacological agents on the allergen induced LAR is also determined using a "same dose" challenge; this method is also often used when studying the EAR.

Conventional β₂ agonists and tolerance

Tolerance to the functional antagonism effect of inhaled β₂ agonists has generally been assessed 10 hours (salbutamol, terbutaline) to 36 hours (salmeterol) after discontinuing a 1–5 week course of the agent. This is compared with the functional antagonism measured before the

β₂ agonist treatment period^{4,11,15} or after a cross-over blinded placebo period.^{10,16} The percentage change in functional antagonism, as calculated in table 1, can be expressed by comparing the shift in doubling doses (dd) before and after dosing by the formula:

$$\frac{[\text{dd (pre)} - \text{dd (post)}]}{\text{dd (pre)}} \times 100$$

For the same dose challenges – for example, exercise – this is expressed as:

$$\frac{\Delta\% \text{ inhibition (pre - post)}}{\% \text{ inhibition (pre)}} \times 100$$

Tolerance to the functional antagonist effect of β₂ agonists of conventional duration has routinely been found after their regular use. Gibson *et al* demonstrated that regular use of ingested salbutamol (4 mg four times daily for 2–5 weeks) in six adult subjects resulted in tolerance to the acute bronchoprotective effect of inhaled salbutamol against exercise induced bronchospasm. Protection was 78% before and 54% after treatment.¹⁵ In the same study, inhaled salbutamol 800 μg per day in six adolescents resulted in a slight and non-significant loss of the bronchoprotective effect against exercise.¹⁵ Vathenen *et al* studied airway responsiveness to histamine and regular use of inhaled terbutaline 750 μg three times daily for two weeks. This study demonstrated rebound airway hyperresponsiveness to histamine maximal 23 hours after stopping treatment, and a substantial loss of bronchoprotective effect of terbutaline against histamine which was greater in the afternoon than in the morning.¹⁶ A similar study from the same group examined broxaterol 400 μg three times daily and salbutamol 200 μg three times daily for three weeks. Similar results were seen with rebound histamine hyperresponsiveness maximal at 35 hours and lasting for up to 59 hours.¹⁷ There was less improvement in histamine PD₂₀ both in the morning and in the afternoon after the three week treatment period. Salbutamol initially shifted the histamine PD₂₀ by about three doubling doses and, after completion of the study, this was reduced to a little over two doubling doses. Broxaterol showed less protection at all times. This approximate 25% reduction in bronchoprotection of salbutamol against histamine was not statistically significant in these 11 asthmatic subjects. O'Connor *et al* assessed airway responsiveness to methacholine and AMP before and after one week of treatment with terbutaline 500 μg four times daily in 12 subjects.⁴ Their study design did not include re-establishing the baseline PC₂₀ values after each treatment. The methacholine and AMP PC₂₀ values were determined following a one week treatment period with terbutaline or placebo and the PC₂₀ value after a week of terbutaline treatment was compared with the baseline PC₂₀ value following a week of placebo. Terbutaline initially produced a 2.7 doubling dose shift of methacholine PC₂₀ compared with a 3.8 doubling dose shift of the AMP PC₂₀

Table 1 Functional antagonism before and after regular use of β_2 agonists

β_2 agonist	Stimulus	n	Duration	Functional antagonism†				Ref
				Time	Pre	Post	% loss	
Salbutamol (po)	Exercise	6	2–5 wk	10 min	~78%	~54%	~30% (*)	15
(inhaled)	Exercise	6	2–5 wk	10 min	~95%	~82%	~13% (NS)	15
Terbutaline	Histamine	8	2 wk	2 h am	~2.9 dd	~1.7 dd	40% (**)	16
				2 h pm	~3.0 dd	~0.5 dd	82% (**)	16
Salbutamol	Histamine	11	3 wk	1 h am	~3 dd	~2 dd	33% (NS)	17
				1 h pm	~4 dd	~3 dd	25% (NS)	17
Broxaterol	Histamine	11	3 wk	1 h am	~2 dd	~1.5 dd	25% (NS)	17
				1 h pm	~2 dd	~1.5 dd	25% (NS)	17
Terbutaline	Methacholine	12	1 wk	20 min	2.7 dd	2.2 dd	19% (*)	4
	AMP	12	1 wk	20 min	3.8 dd	1.7 dd	55% (**)	4
Salbutamol	Methacholine	12	2 wk	10 min	3.2 dd	2.6 dd	22% (*)	10
	Allergen	11	2 wk	10 min	3.7 dd	2.5 dd	27% (*)	10
Salbutamol (alone)	Methacholine	13	1 wk	10 min	3.0 dd	2.0 dd	33% (**)	18
(with budesonide)				10 min	2.9 dd	2.2 dd	24% (**)	18
Salbutamol	Methacholine	10	1 wk	10 min	3.4 dd	2.6 dd	24% (**)	19
200 µg/day				10 min		2.6 dd	24% (**)	19
400 µg/day				10 min		2.5 dd	26% (**)	19
800 µg/day				10 min		2.5 dd	26% (**)	19
Salbutamol	Exercise	10	1 wk	5 min	94%	85%	10% (?)	22
Salbutamol	Methacholine	12	4 wk	1 h	3.3 dd	1.0 dd	70% (**)	11
			8 wk	1 h		1.0 dd	70% (**)	11
Salmeterol	Methacholine	15	1 mo	12 h	1.7 dd	0.7 dd	59% (**)	25
			2 mo	12 h		1.2 dd	29% (**)	25
			3 mo	12 h		0.7 dd	59% (**)	25
			4 mo	12 h		0.8 dd	53% (**)	25
Salmeterol	Exercise	12	4 wk	6 h	66%	27%	54%	26
				12 h	40%	17%	58%	26
Salmeterol	Allergen	8	1 wk	1 h	86%	13%	85%	27
Salmeterol	Methacholine	12	3.5 days	1 h	3.3 dd	1.6 dd	52% (**)	28
				24 h††	3.7 dd	1.9 dd	53% (**)	28
Salmeterol and inhaled corticosteroid	Methacholine	8	3.5 days	1 h	2.8 dd	1.6 dd	43% (**)	29
				24 h††	2.6 dd	1.7 dd	35% (**)	29
Formoterol	Methacholine	17	2 wk	12 h	1.9 dd	0.6 dd	68% (*)	30
Salmeterol	Methacholine	10	4 wk	12 h	0.9 dd	1.2 dd	(NS)	31
			8 wk	12 h		0.7 dd	(NS)	31

† Functional antagonism: Time = timing of assessment of functional antagonism; Pre = before regular use of β_2 agonist; % = % protection in "same dose" challenges; dd = doubling dose shift of PC₂₀, PC₁₅, PD₂₀, etc; ~ = approximate (extrapolated from a graph); †† = 24 h after salmeterol completed, tested 10 min post-salbutamol. *p<0.05, **p<0.01.

(p<0.001). This difference was attributed to the combined effect of terbutaline on mast cell β_2 receptors and smooth muscle β_2 receptors in protecting against AMP, and on smooth muscle β_2 receptors only in protecting against methacholine.⁴ After the one week treatment period terbutaline shifted the methacholine PC₂₀ by 2.2 doubling doses; this 19% loss of protection was significant (p<0.05). By contrast, there was a much greater loss of broncho-protective effect against AMP as terbutaline treatment only shifted the AMP PC₂₀ by 1.7 doubling doses, a reduction of 55% from the 3.8 doubling doses (p<0.001). The interpretation of this greater loss of protection against inhaled AMP, a mast cell stimulus, was that β_2 receptors on mast cells might be more susceptible to tolerance than are the β_2 receptors on smooth muscle.⁴

Using this study as a model we investigated the effect of a two week course of salbutamol 200 µg four times daily on airway responsiveness to methacholine (n=12) and allergen (n=11).¹⁰ The study design was different from that of O'Connor *et al* in that we re-established methacholine and allergen PC₂₀ baseline values following each treatment period. We found that the methacholine PC₂₀ baseline did not change, but the initial protection of 3.2 doubling doses was reduced to 2.5 doubling doses after two weeks of salbutamol (p=0.026), a 22% loss of protection. The protection against allergen was initially 3.7 doubling doses (greater than the protection against methacholine but not significant) and it fell by 32% to 2.5 doubling doses after the

two week treatment period (p=0.025). The most striking finding in this study was the unexpected observation of a highly significant increase in airway responsiveness to allergen after two weeks of treatment with salbutamol. There was almost a doubling of airway responsiveness to allergen (p=0.0009).¹⁰ In a follow up study we showed that salbutamol 200 µg four times a day for seven days resulted in a loss of bronchoprotection against methacholine from 2.9 doubling doses initially to 2.0 doubling doses (31% loss) after one week of salbutamol.

In the same subjects, in a blinded crossover trial, high dose budesonide (1600 µg per day) was compared with high dose budesonide plus salbutamol. An equivalent tolerance to broncho-protection was found, with the initial protection falling from 2.9 doubling doses to 2.25 doubling doses, a 22% loss, not significantly different from the comparison between placebo and salbutamol. In this same study, although budesonide did improve the allergen PC₁₅, it did not prevent the parallel increase in airway responsiveness to allergen when salbutamol and budesonide were administered concurrently.¹⁸ We have investigated these two models in a double blind randomised crossover study, comparing placebo with salbutamol in doses of 200 µg, 400 µg, and 800 µg per day each for one week in 10 subjects. Salbutamol produced a 3.4 doubling dose improvement in methacholine PC₂₀ after placebo compared with a 2.6 doubling dose improvement following the 200 and 400 µg per day treatment periods, and a 2.5 doubling dose improvement following

the 800 µg per day treatment period.¹⁹ This represents a 24–26% loss of the functional antagonism effect, which was not significantly different between the three doses of salbutamol. In the same study airway responsiveness to allergen did not change after 200 and 400 µg salbutamol per day for a week but did increase significantly, again by almost twofold, after 800 µg salbutamol per day for a week.¹⁸ In two additional studies which did not assess the functional antagonist effect, the late asthmatic response to allergen was shown to be almost double after a week of regular salbutamol treatment compared with placebo; these studies were both done using the “same dose” allergen challenge model.^{20,21}

Inman *et al* studied the effect of salbutamol 200 µg four times daily and exercise. Following salbutamol there was a lower FEV₁ and a lower FEV₁ after exercise, both with and without salbutamol used immediately before exercise.²² The protection against exercise induced bronchoconstriction was excellent both after a week of placebo (94% protection) and a week of salbutamol (85% protection).

Long acting β_2 agonists and tolerance

Tolerance has also been found with the long acting inhaled β_2 agonists, salmeterol and formoterol. After regular use of either of these agents it is possible to demonstrate tolerance to bronchodilation as shown by a shift of the β_2 agonist dose–response curve to the right without a loss of maximum bronchodilation.^{23,24} Tolerance to functional antagonism, however, appears to be greater than tolerance to bronchodilation.

Cheung *et al* performed a parallel placebo controlled trial of salmeterol 50 µg twice daily for eight weeks with 12 subjects receiving placebo and 12 receiving active drug. Following the first dose of salmeterol there was a tenfold improvement in methacholine PC₂₀ (3.3 doubling doses). After a 36 hour washout period at four and eight weeks there was no change in FEV₁, no change in bronchodilation, but a dose of salmeterol at these two time periods offered only a twofold improvement in methacholine PC₂₀ (that is, one doubling dose). This represents approximately a 70% loss of bronchoprotective effect. In this study there was no rebound hyperresponsiveness after the eight week treatment was discontinued.¹¹ In a recent parallel study in children of salmeterol 50 µg twice daily (n = 15) versus salbutamol 200 µg twice daily (n = 15) similar results were seen.²⁵ Twelve hours after the first dose of salmeterol the methacholine PD₂₀ increased by 1.7 doubling doses. After 1–4 months the methacholine PD₂₀ was shifted, after a dose of salmeterol, by 0.7, 1.15, 0.65, 0.76 doubling doses at one, two, three, and four months, respectively; these were significantly less than the protection after the first dose (p < 0.001). Methacholine PD₂₀ measured 12 hours after salbutamol in the parallel group showed no changes at any time.

Ramage *et al* studied the airway response to exercise six and 12 hours after the first and last dose of salmeterol, 50 µg twice daily for four

weeks. Since exercise was studied, a “same dose” challenge was used. The first dose of salmeterol produced a 66% reduction in the exercise induced fall in FEV₁ at six hours and a 40% reduction in the fall in FEV₁ at 12 hours. The last dose produced only a 27% reduction in exercise induced bronchoconstriction at six hours and an 18% reduction at 12 hours, the results with the last dose being not statistically different from those with placebo, despite a trend. These results represent a 55–60% loss of bronchoprotection.²⁶

Gianinni *et al*, in a published abstract, studied eight subjects who undertook a same dose allergen challenge one hour after the first and last dose of salmeterol and placebo administered for one week in a crossover study. The first dose of salmeterol almost completely inhibited the early asthmatic response (86% inhibition), whereas the last dose of salmeterol was not significantly different (13% inhibition) from placebo. This represents a 77% loss of bronchoprotection.²⁷

We have studied the time course of the development of tolerance to the bronchoprotective effect of salmeterol against methacholine. Methacholine PC₂₀ was measured one hour after the first, third, fifth, and seventh doses of twice daily salmeterol in a double blind placebo crossover study. Twenty four hours after salmeterol was discontinued the methacholine PC₂₀ was measured 10 minutes after 200 µg inhaled salbutamol. By the third dose of salmeterol the bronchoprotective effect was reduced from 3.3 to 2.4 doubling doses (p = 0.009) and continued to fall to a protection of only 1.5 doubling doses after the seventh dose. The PC₂₀ after salbutamol on day 5 was also reduced from a 3.7 doubling dose shift 24 hours after the seventh dose of placebo to 1.9 doubling dose shift 24 hours after the seventh dose of salmeterol.²⁸ Similar findings were reported in a subsequent study of identical design in eight subjects with more severe asthma who required regular inhaled corticosteroids.²⁹ The initial dose of salmeterol provided an improvement of approximately three doubling doses in methacholine PC₂₀, while the last dose provided less than 1.5 doubling dose protection. The loss of protection was again significant by the second day (p = 0.031) and again extended to salbutamol given 24 hours after the last dose.

Yates *et al* assessed methacholine PC₂₀ after the first and last dose of a two week treatment period of formoterol 24 µg twice daily. Twelve hours after the first dose of formoterol there was a 1.9 doubling dose improvement in methacholine PC₂₀ compared with a 0.5 doubling dose increase 12 hours after the last dose. This represents a 74% loss of bronchoprotection. This study also failed to show any significant rebound hyperresponsiveness at 36 hours, 60 hours, 108 hours, and two weeks after the two week course of formoterol.³⁰ The FEV₁ was lower 36 hours after formoterol than after placebo, but was not lower at other time periods.

The one contradictory study published was that by Booth *et al* who studied 26 asthmatic

patients, 19 of whom were on maintenance inhaled corticosteroids. They were allowed free access to inhaled β_2 agonist before and during the trial as "rescue" medication, so any tolerance may have been present at the beginning of the study. The study was a parallel, double blind, eight week trial with 10 subjects completing the salmeterol arm and 12 the placebo arm. Methacholine PC₂₀ was measured 12 hours after the first dose and repeated 12 hours after a dose at four and eight weeks. The functional antagonism effect after the first dose was less than one doubling concentration of methacholine and there was no loss over time.³¹ It is likely that the negative results in this trial were caused by the pre-trial (and continued) use of rescue inhaled β_2 agonist.

The results of all of the trials quoted are summarised in table 1. Whereas the short acting β_2 agonists generally appear to result in a 20–30% loss of bronchoprotection, the longer acting β_2 agonists consistently seem to cause a 50–75% loss of bronchoprotection. Although still difficult to demonstrate tolerance to bronchodilation, this is easier for the longer acting than for the conventional β_2 agonists.^{23 24}

Conclusions

The published studies are very consistent. Tolerance to the functional antagonist effect of inhaled β_2 agonists develops with all agents and to all stimuli (table 1). Significant tolerance can be seen at very low doses (salbutamol 200 μ g per day for seven days)¹⁹ and can develop very rapidly (by the third dose of twice daily salmeterol).^{28 29} Corticosteroids do not prevent development of this tolerance.^{18 29} The mast cell stimuli (AMP, allergen, possibly exercise) appear to be more prone to tolerance than are the direct chemical stimuli.⁴ In addition to tolerance to the bronchoprotective effect, regular use of inhaled β_2 agonists increases baseline airway responsiveness to allergens – both early^{10 18 19} and late^{20 21} – such that the post-salbutamol allergen PC₂₀ after two weeks of salbutamol was almost two doubling doses lower than after placebo.¹⁰

The clinical relevance of these findings remains uncertain. Even when tolerance develops, particularly with the short acting inhaled β_2 agonists, there remains a considerable functional antagonist effect. However, inhaled β_2 agonists are often used clinically for their functional antagonist effect – for example, before exercise, exposure to cold air, and exposure to allergens. It therefore seems likely that the important loss of bronchoprotection against allergen and exercise seen particularly with the long acting inhaled β_2 agonists might have important clinical relevance. The enhanced airway response to allergen, particularly the late response, may be associated with increased allergen induced airway inflammation.²¹ This may explain the observation of Manolitsas *et al* of increased levels of eosinophils in bronchial biopsy specimens taken after regular treatment with salbutamol.³² These findings may also explain the appearance

of increased airway responsiveness (or rebound airway responsiveness) seen in some studies^{16 17 33 34} but not in others.^{10 11 18 19 30}

The authors would like to thank Jacquie Bramley for assisting in the preparation of this manuscript.

- 1 Taylor DR, Sears MR, Cockcroft DW. The beta-agonist controversy. In: Cockcroft DW, Dosman JA, eds. *Obstructive lung diseases Part II: Asthma, sleep, occupational exposures and AIDS*. Med Clin North Am 1996;80:719–48.
- 2 Ahrens RC, Bonham AC, Maxwell GA, Weinberger MW. A method for comparing the peak intensity and duration of action of aerosolized bronchodilators using bronchoprovocation with methacholine. *Am Rev Respir Dis* 1984; 129:903–6.
- 3 Tattersfield AE. Tolerance to beta-agonists. *Bull Eur Physiol Pathol Respir* 1985;21:1–5.
- 4 O'Connor BJ, Aikman SL, Barnes PJ. Tolerance to the nonbronchodilator effects of inhaled β_2 -agonists in asthma. *N Engl J Med* 1992;327:1204–8.
- 5 Cockcroft DW, Hargreave FE. Airway hyperresponsiveness: definition, measurement, and clinical relevance. In: Kaliner MA, Barnes PJ, Persson CGA, eds. *Asthma: its pathology and treatment*. New York: Marcel Dekker, 1991: 51–72.
- 6 Pauwels R, Joos G, Van Der Straeten M. Bronchial hyperresponsiveness is not bronchial hyperresponsiveness is not bronchial asthma. *Clin Allergy* 1988;18:317–21.
- 7 Cockcroft DW, Killian DN, Mellon JJA, Hargreave FE. Bronchial reactivity to inhaled histamine: a method and clinical survey. *Clin Allergy* 1977;7:235–43.
- 8 Finnerty JP, Wilmot C, Holgate ST. Inhibition of hypertonic saline-induced bronchoconstriction by terfenadine and flurbiprofen. *Am Rev Respir Dis* 1989;140:593–7.
- 9 Anderson SD, Schoeffel RE, Finney M. Evaluation of ultrasonically nebulised solutions for provocation testing in patients with asthma. *Thorax* 1983;38:284–91.
- 10 Cockcroft DW, McParland CP, Britto SA, Swystun VA, Rutherford BC. Regular inhaled salbutamol and airway responsiveness to allergen. *Lancet* 1993;342:833–7.
- 11 Cheung D, Timmers MC, Zwinderman AH, Bel EH, Dijkman JH, Sterk PJ. Long-term effects of a long-acting β_2 -adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. *N Engl J Med* 1992;327:1188–203.
- 12 Lai CKW, Twentyman OP, Holgate ST. The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in non-specific bronchial responsiveness. *Am Rev Respir Dis* 1989; 140:917–23.
- 13 Cockcroft DW, McParland CP, O'Byrne PM, Manning P, Friend JL, Rutherford BC, *et al*. Beclomethasone given after the early asthmatic response inhibits the late response and the increased methacholine responsiveness and cromolyn does not. *J Allergy Clin Immunol* 1993;91:1163–8.
- 14 Anderson S, Seale JP, Ferris L, Schoeffel R, Lindsay DA. An evaluation of pharmacotherapy for exercise-induced asthma. *J Allergy Clin Immunol* 1979;64:612–24.
- 15 Gibson GJ, Greenacre JK, Konig P, Conolly ME, Pride NB. Use of exercise challenge to investigate possible tolerance to beta-adrenoceptor stimulation in asthma. *Br J Dis Chest* 1978;72:199–206.
- 16 Vathenen AS, Knox AJ, Higgins BG, Britton JR, Tattersfield AE. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. *Lancet* 1988;ii:554–7.
- 17 Wahedna I, Wong CS, Wisniewski AFZ, Pavord ID, Tattersfield AE. Asthma control during and after cessation of regular beta₂-agonist treatment. *Am Rev Respir Dis* 1993;148:707–12.
- 18 Cockcroft DW, Swystun VA, Bhagat R. Interaction of inhaled β_2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. *Am J Respir Crit Care Med* 1995;152:1485–9.
- 19 Bhagat R, Swystun VA, Cockcroft DW. Salbutamol-induced increased airway responsiveness to allergen and reduced protection vs. methacholine: dose-response. *J Allergy Clin Immunol* 1996;97:47–52.
- 20 Cockcroft DW, O'Byrne PM, Swystun VA, Bhagat R. Regular use of inhaled albuterol and the allergen-induced late asthmatic response. *J Allergy Clin Immunol* 1995;96:44–9.
- 21 Gauvreau GM, Watson RM, Jordana M, Cockcroft D, O'Byrne PM. The effect of regular inhaled salbutamol on allergen-induced airway responses and inflammatory cells in blood and induced sputum. *Am J Respir Crit Care Med* 1995;151:A39.
- 22 Inman MD, O'Byrne PM. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. *Am J Respir Crit Care Med* 1996;153:65–9.
- 23 Newnham DM, Grove A, McDevitt DG, Lipworth BJ. Subsensitization of bronchodilator and systemic β_2 adrenoceptor responses after regular twice daily treatment with formoterol dry powder in asthmatic patients. *Thorax* 1995;50:497–504.
- 24 Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. *Lancet* 1995;346:201–6.
- 25 Verberne AAPH, Hop WCJ, Creyghton FBM, van Rooij RWG, van den Berg M, de Jongste JC, *et al*. Airway responsiveness after a single dose of salmeterol and during

- four months of treatment in children with asthma. *J Allergy Clin Immunol* 1996;**97**:938–46.
- 26 Ramage L, Lipworth BJ, Ingram CG, Cree JA, Dhillon DP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. *Respir Med* 1994;**88**:363–8.
 - 27 Giannini D, Carletti A, Dente FL, Bacci E, Bancalari L, Di Franco A, *et al.* Tolerance to salmeterol in allergen induced bronchoconstriction. *Am J Respir Crit Care Med* 1995;**151**:A39.
 - 28 Bhagat R, Kalra S, Swystun VA, Cockcroft DW. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. *Chest* 1995;**108**:1235–9.
 - 29 Kalra S, Swystun VA, Bhagat R, Cockcroft DW. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. *Chest* 1996;**109**:953–6.
 - 30 Yates DH, Sussman HS, Shaw MJ, Barnes PJ, Chung KF. Regular formoterol treatment in mild asthma: effect on bronchial responsiveness during and after treatment. *Am J Respir Crit Care Med* 1995;**152**:1170–4.
 - 31 Booth H, Fishwick K, Harkawat R, Devereux G, Hendrick DJ, Haydn Walters E. Changes in methacholine induced bronchoconstriction with the long acting β_2 agonist salmeterol in mild to moderate asthmatic patients. *Thorax* 1993;**48**:1121–4.
 - 32 Manolitsas ND, Wang J, Devalia JL, Trigg CJ, McAulay AE, Davies RJ. Regular albuterol, nedocromil sodium, and bronchial inflammation in asthma. *Am J Respir Crit Care Med* 1995;**151**:1925–30.
 - 33 Kraan J, Koeter GH, Van Der Mark Th W, Boersma M, Kukler J, Sluiter HJ, *et al.* Dosage and time effects of inhaled budesonide on bronchial hyperreactivity. *Am Rev Respir Dis* 1988;**137**:44–8.
 - 34 Kerribijn KF, van Essen-Zandvliet EEM, Neijens HJ. Effects of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. *J Allergy Clin Immunol* 1987;**79**:653–9.